申请人:Kali-Chemie Aktiengesellschaft
公开号:US03966735A1
公开(公告)日:1976-06-29
Piperazine derivatives having the following general formula ##EQU1## in which n is 2 or 3, X is an oxy or thio radical, and A and B are each a radical of the group consisting of phenyl radicals containing at most three substituents of the group consisting of nitro, trifluoromethyl, halogen, cyano, and alkyl, alkoxy, alkylthio, acyl, and alkylsulfonyl radicals containing at most 6 carbon atoms, and similar cycloalkyl and cycloalkylalkyl radicals, their acid addition salts, processes for their production, and pharmaceutical compositions containing the same. The compounds have a very favorable action on the central nervous system and are effective agents for the treatment of anxiety states, psychoses, emotional disturbances, aggressive tendencies, and can be used generally for the treatment of psychiatrically disturbed and psychoneurotic patients.
哌嗪衍生物具有以下一般公式##EQU1##其中n为2或3,X为氧基或硫基,A和B分别为苯基基团,最多含有三个取代基,所述取代基包括硝基、三氟甲基、卤素、氰基、烷基、烷氧基、烷硫基、酰基和最多含有6个碳原子的烷基磺酰基基团,以及类似的环烷基和环烷基烷基基团,它们的酸盐,其生产方法,以及含有它们的药物组合物。这些化合物对中枢神经系统有非常有利的作用,是治疗焦虑状态、精神病、情绪障碍、攻击性倾向的有效药物,并且通常可用于治疗精神紊乱和神经症患者。